Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04935684 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation

Study acronym: TMF-Allo
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria expanded, about 13 words Show 4 more changesShow less
    • Secondary endpoints: details revised at 8 of 20 entries
    • Site details revised at 13 of 20 sites
    • Publications: details revised at 1 of 1 entry
    • Study description expanded, about 5 words
  2. Primary completion date: Oct 2026 to May 2030
    • Study completion date: Dec 2027 to May 2030
    • Site details revised at 1 of 20 sites
    v6
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Nov 2022 to Dec 20, 2022
    • Site details revised at 20 of 20 sites
    v5
  4. Primary completion date: Oct 2025 to Oct 2026
    • Start date: Aug 2021 to Nov 2022
    • Study sites: 0 to 20
    v4
  5. Start date: Jun 2021 to Aug 2021v3
  6. Secondary endpoints: details revised at 4 of 20 entriesv2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
University Hospital, Clermont-Ferrand
314 trials monitored
See 5 trials at risk
Leukemia
2,948 trials monitored
See 180 trials at risk
Non-Hodgkin Lymphoma
2,013 trials monitored
See 115 trials at risk
Multiple Myeloma
1,261 trials monitored
See 80 trials at risk
and 3 more diseases
The aim of this study is to assess the Fecal Microbiota Transplantation (FMT) efficacy in the prevention of allogeneic hematopoietic stem cell transplantation (allo-HSCT) complications and particularly Graft versus Host Disease (GvHD). The hypothesis of this study is that allogeneic FMT may improve outcomes of these patients.
Trial Details
NCT Number NCT04935684
Lead Sponsor University Hospital, Clermont-Ferrand
Collaborators: Ministry of Health, France, French Society of Hematology
Conditions
(from sponsor)		 Acute Leukemia in Remission, Myelodysplastic Syndromes, Myeloproliferative Syndrome, Hodgkin Lymphoma, Lymphoma, Non-Hodgkin, Myeloma, Chronic Lymphocytic Leukemia
Related terms Graft vs Host Disease, Hematologic Neoplasms, Hodgkin Disease, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Neoplasms, Plasma Cell
Enrollment 150 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov